SiBone (NASDAQ:SIBN) executives highlighted record revenue, increased physician adoption, and a shift to profitability metrics in the company’s fourth-quarter 2025 earnings call, while outlining ...
BioMarin Pharmaceutical (NASDAQ:BMRN) executives highlighted record 2025 revenue, expanding profitability, and multiple upcoming pipeline and regulatory milestones during the company’s fourth-quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results